Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2017–2021

BBDiag · Blood Biomarker-based Diagnostic Tools for Early Stage Alzheimer’s Disease

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2017-01-01 → 2021-12-31
Финансиране от ЕС
3 434 981 €
Участници
14
Схема
MSCA-ITN

Линиите свързват координатора с партньорите. За проекти отпреди 2014 г. CORDIS не винаги дава точни координати. Тези точки са на ниво град или държава.

Накратко на български

Биомаркерите в кръвта се анализират, за да се създадат инструменти за ранна диагностика на болестта Алцхаймер. Това помага за подобряване на грижите към пациентите и разработването на превантивни стратегии и терапии.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Blood Biomarker-based Diagnostic Tools for Early Stage Alzheimer’s Disease

The aim of the BBDiag project was to train a new generation of ESRs for early AD diagnosis based on blood biomarkers. Despite of the notable recent advances in AD biomarkers and diagnostics, dementia is still one of the Societal Challenges listed by the UN and EU. BBDiag responded to such a need and established this ETN for blood based early-AD diagnostics. BBDiag Fellows were trained under the Vitae Researcher Development Framework innovatively combined with the BBDiag platform for gaining interdisciplinary skills as well as personal quality, creative thinking and business mind-set. The ETN had a highly innovative research programme for the discovery of AD biomarkers, development of novel biosensing techniques and point of care tools, and for technological exploitation of the diagnostics. These advances will strongly support improved care provision and development of disease-modifying treatments and preventive strategies for AD patients. More importantly, BBDiag delivered its first generation of highly-skilled, creative and entrepreneurial Fellows, setting them on a path to successful careers in academia or industry to ensure that the medical and societal challenges imposed by AD are met.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Alzheimer’s disease (AD) affects more than 7 million people in Europe and this figure is expected to double every 20 years. Despite intensive efforts, no disease-modifying treatments or preventive strategies are available. The lack of specific, sensitive and minimally invasive diagnostics to identify people with early-stage AD to be included in clinical drug intervention trials is among the main reasons for many notable trial failures. The main challenges in developing the required diagnostics are identification of AD biomarkers and development of their detection techniques. The complex and interdisciplinary nature of the research underlines the need for innovative training of a new generation of researchers in the field. BBDiag responds to such a need and establishes a much-needed ETN for blood based early-AD diagnostics to address these challenges. It brings together leading academic and industrial experts from five major consortia in Europe and uses their synergies to build a triple-i research & training platform with the required multidisciplinary expertise and cutting-edge technologies. BBDiag Fellows will be trained under the Vitae Researcher Development Framework innovatively combined with the BBDiag platform for gaining interdisciplinary scientific and transferable skills as well as personal quality, creative thinking and business mind-set. The ETN has a highly innovative research programme for the discovery of AD biomarkers, development of novel biosensing techniques and point of care tools, and for technological exploitation of the diagnostics. These advances will strongly support improved care provision and development of disease-modifying treatments and preventive strategies for AD patients. More importantly, BBDiag will deliver its first generation of 13 highly-skilled, creative and entrepreneurial Fellows, setting them on a path to successful careers in academia or industry to ensure that the medical and societal challenges imposed by AD are met.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз